HealthQuiet 38d · day 38
Amylyx's GLP-1 antagonist avexitide succeeds in Phase 3 trial
The biotech company's experimental drug halved blood sugar crashes in post-bariatric hypoglycemia patients, sending stock up 55%.
What to know
- Amylyx's GLP-1 antagonist avexitide hit all primary and secondary endpoints in Phase 3 testing for post-bariatric hypoglycemia, a serious condition in weight-loss surgery patients.
- The drug reduced severe low blood sugar episodes by 50%, addressing a significant unmet medical need.
- Stock jumped 55% and hit a 3-year high; the company is moving toward regulatory filing for approval.
- This marks a major repositioning for Amylyx after exiting the ALS market where its previous drug failed.
“Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win”
Fierce Biotech headline · Fierce Biotech ↗
Amylyx Pharmaceuticals biotech company
The record 7 articles and posts · last 30 days